Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
06.05. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
06.05. | Jin Medical International Ltd. - Nasdaq Minimum Bid Price Non-Compliance | 26 | GlobeNewswire (Europe) | Changzhou City, China, May 06, 2025 (GLOBE NEWSWIRE) -- Jin Medical International Ltd. (NASDAQ: ZJYL) (the "Company") today announced that on May 2, 2025, it received a deficiency letter (the "Notice")... ► Artikel lesen | |
JIN MEDICAL INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
25.04. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
24.01. | Jin Medical International Ltd. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SERNOVA BIOTHERAPEUTICS | 0,111 | 0,00 % | Original-Research: Sernova Biotherapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Sernova Biotherapeutics Inc - from First Berlin Equity Research GmbH 02.06.2025 / 13:39 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group.... ► Artikel lesen | |
PLUS THERAPEUTICS | 0,323 | +1,19 % | PLUS THERAPEUTICS, INC. - 8-K, Current Report | ||
ATOSSA THERAPEUTICS | 0,800 | +8,40 % | Ascendiant Capital raises Atossa Genetics stock price target to $7.50 | ||
PING AN HEALTHCARE | 0,755 | 0,00 % | PA GOODDOCTOR (01833): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | ||
MOUNTAIN VALLEY MD | 0,012 | -16,44 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
CO-DIAGNOSTICS | 0,274 | +3,01 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
VERU | 0,525 | -3,40 % | Veru Inc.: Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide ... | --Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial... ► Artikel lesen | |
CYTOSORBENTS | 0,884 | -4,54 % | Cytosorbents Corp: CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update | PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
AMBU | 13,260 | -0,82 % | Ambu A/S: Interim Report For Q2 2024/25 And The Half-year | 7.5.2025 07:00:01 CEST | Ambu A/S |
Half Year financial report
In the second quarter of the 2024/25 financial year, Ambu delivered 11.7% organic revenue growth and a 14.4% EBIT margin before special... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 5,240 | -100,00 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
VOLITIONRX | 0,568 | -3,57 % | VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., May 15, 2025 /PRNewswire/... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 46,650 | +0,26 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
FRESENIUS | 44,290 | +0,11 % | DAX-Check LIVE: Bilfinger, Cancom, Delivery Hero, Fresenius, Gerresheimer, Rheinmetall im Fokus | Der DAX hat den gestrigen Handelstag mit leichten Verlusten beendet. Der deutsche Leitindex schloss 0,28 Prozent tiefer bei 23.930 Punkten. Zwar konnte er sich am Nachmittag vom Tagestief bei 23.740... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 50,32 | -0,40 % | JPMORGAN stuft FMC FRESENIUS MEDICAL CARE AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für FMC mit einem Kursziel von 41,50 Euro auf "Underweight" belassen. Die Anleger warteten auf neue Mittelfristziele und Neuigkeiten... ► Artikel lesen | |
GERRESHEIMER | 47,800 | -2,73 % | EQS-Adhoc: Gerresheimer AG: Anpassung der Prognose für 2025 | EQS-Ad-hoc: Gerresheimer AG / Schlagwort(e): Prognoseänderung/Dividende
Gerresheimer AG: Anpassung der Prognose für 2025
02.06.2025 / 11:40 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen |